2007 Annual Report - Foundation for the National Institutes of Health

007 

ANNUAL REPORT 

PARTNERS FOR INNOVATION, DISCOVERY, LIFE

The foundation plays a unique and important role in 

bringing innovation and private resources together to 

further the mission of NIH. The Foundation 

for NIH has been tremendously 

helpful in forming public-private 

partnerships that benefit the 

public good. 

—Elias A. Zerhouni, M.D. 

Director, 

National Institutes of Health

The Foundation for the National Institutes of Health was established by the 

United States Congress to support the mission of the National Institutes of 

Health (NIH): improving health through scientific discovery. The foundation 

identifies and develops opportunities for innovative public-private partnerships 

involving industry, academia, and the philanthropic community. A non-profit, 

501(c)(3) corporation, the foundation raises private-sector funds for a broad 

portfolio of unique programs that complement and enhance NIH priorities 

and activities.

Table of Contents 

Letter from the Chairman and Executive Director 1 

Year in Review 2 

The Biomarkers Consortium 4 

Osteoarthritis Initiative – OAI 7 

Alzheimer’s Disease 

Neuroimaging Initiative – ADNI 8 

Genetic Association Information Network – GAIN 9 

Grand Challenges in Global Health – GCGH 11 

Comprehensive T Cell Vaccine Immune 

Monitoring Consortium – CTC-VIMC 12 

Global Health Security Initiative – GHSI 13 

Collaborative Summit on Breast Cancer Research 15 

AVON-NCI Progress for Patients Awards Program 16 

Targeted Cancer Therapies Tutorials 17 

Measures for Clinical Trials of Treatment of Cognition 19 

Clinical Research Training Program – CRTP 20 

Program Listing 21 

Edmond J. Safra Family Lodge 22 

Endowments 23 

Financial Summary 24 

Donors 26 

Board of Directors 32 

Advisory Boards 33 

Staff 36

MAY 2008 

Dear Friends: 

2007 was especially gratifying for the Foundation for NIH, as some of the largest and 

most complex programs we’ve ever undertaken have begun to bear fruit. As the congressionally 

chartered non-profit organization that supports the life-saving research 

mission of the National Institutes of Health, our promise has been not only to create 

public-private partnerships that advance scientific discovery, but to do so efficiently 

and effectively. 

In a little over a year, The Biomarkers Consortium, a ground-breaking partnership 

focused on developing new biomarkers, involved over 75 organizations across 

the public, private, academic, and non-profit sectors. Currently, it has two projects 

underway and several more in development. The Alzheimer’s Disease Neuroimaging 

Initiative, another ambitious program, was able to expand its scope significantly, 

thanks to additional support secured by the foundation. 

Data are emerging from two other major programs: within 18 months of its establishment, 

the Genetic Association Information Network (GAIN) completed six major 

genotyping studies, depositing the results for use by genetic researchers in a National 

Library of Medicine database; while the Osteoarthritis Initiative began posting data 

and images on its secure web site. These steps help fulfill the foundation’s commitment 

to making data available to the broadest research audience possible, spurring further 

work to speed our understanding of disease and the therapies to prevent or treat it. 

Hundreds of researchers from dozens of countries are already using these data. 

In 2007, the foundation also expanded its unique ability to convene disparate stakeholders 

to address significant common goals. It initiated important summits focused 

on breast cancer, age-related brain changes, and global emergency preparedness. As 

a non-commercial organization whose sole agenda is advancing human health and 

which is uniquely authorized by Congress to support NIH, the foundation is often 

the only entity that can make such collaboration possible. 

Finally, the foundation is proud of its role in supporting programs whose innovative 

methods, tools, and procedures are setting the standard in research and training, and 

serving as a model for others to follow. 

2007 saw the Foundation for NIH deliver abundant evidence of its commitment 

and ability to create and manage public-private partnerships to advance human 

health. By judiciously leveraging the expertise, resources, and funding of NIH and 

many other individuals and institutions, we continue to earn the trust and confidence 

of our partners, donors, and the public as a whole. 

Charles A. Sanders, M.D. 

Chairman 

Amy McGuire Porter 

Executive Director

YEAR IN REVIEW 

Initiatives funded and facilitated by the Foundation for NIH in 2007 addressed a broad range of public health challenges 

through both traditional and innovative approaches. Whether employing practiced scientific methods in new 

fields of study, applying the latest technological tools to intractable problems, or focusing experts of varying perspectives 

around a common goal, these partnerships represent new paradigms on the path to discovery. While each program is 

unique in its structure and strategies, a feature common to all is unprecedented collaboration—collaboration that will 

stretch resources further and, ultimately, advance human health. Some highlights from 2007: 

The biomarkers consortium 

Grand Challenges 

in Global Health 

This unprecedented research initiative, which aims to overcome 

scientific obstacles to solving major health challenges of the 

developing world, registered further progress on several fronts, 

including: severe malaria in children, chronic infection, nutritional 

value of crops, insect control, and others. The partnership funds 43 

promising projects drawing on resources of more than $436 million. 

The consortium launched its first two projects—studying 

whether FDG-PET imaging can measure the effectiveness of 

certain drugs against two types of tumors: lymphoma and lung 

cancer. So far, the foundation has raised $6.43 million from nine 

private-sector donors for these projects; augmenting the $3.75 

million in public funds and in kind contributions committed by 

the National Cancer Institute. 

Discovery Society 

The Discovery Society is the foundation’s principal way of involving many supportive individuals in the 

work of the National Institutes of Health. Funds raised from generous individuals provide the necessary 

platform for the support of the programs on these pages: major collaborative and multidisciplinary projects 

that would be too complex or risky for any one organization to undertake alone. In this age of declining 

government resources, gifts of every size play an especially important role in advancing the life-saving 

work of NIH. Members of the Discovery Society are listed on page 26. 

2 | 2007 Annual report

Global Health Security Initiative 

The United States for the first time hosted this annual meeting, and the 

foundation was a lead sponsor. Formed in 2001, the GHSI aims to protect 

public health and security by improving preparedness for and response to 

terrorist and health threats. U.S. Health and Human Services Secretary 

Michael O. Leavitt and seven European, Asian, and North American 

counterparts addressed potential threats, risk management, and network 

and communications issues. 

GAIN 

Genetic Association 

Information Network 

This project completed genotyping of more 

than 18,000 samples for six major common 

disease studies already underway and granted 

funds to researchers to analyze the results. The 

work focused on attention deficit hyperactivity 

disorder, type I diabetes, major depression, 

psoriasis, schizophrenia, and bi-polar disorder. 

The foundation raised $26 million in cash and 

resources for the network. 

ADNI 

Alzheimer’s Disease 

Neuroimaging Initiative 

The study completed enrollment and is monitoring 823 participants 

for normal, mildly impaired, and Alzheimer’s disease-related 

brain changes. Test results and images are being cataloged in 

a comprehensive database that will spur further research. The 

foundation has raised nearly $25 million for this effort. 

The Foundation for NIH: A Unique Catalyst for 

Public-Private Partnerships 

The Foundation for NIH was established by the U.S. Congress and began operations in 1996 to serve as a 

non-profit catalyst for public-private partnering in support of research of the National Institutes of Health. 

That unique role affords the foundation unparalleled interaction with key personnel at NIH and at the same 

time the entrepreneurial mandate to involve a broad range of public and private entities, including foreign 

partners and for-profit institutions. 

To date, the foundation has raised more than $410 million and facilitated over 50 projects. A flexible 

infrastructure, combined with disciplined scientific, administrative, and program-management capabilities, 

allows the foundation to create innovative, successful partnerships that benefit all parties. 

Foundation for for the the National Institutes of Health of Health | 3 www.fnih.org | 3

The Biomarkers Consortium 

Established in late 2006, The Biomarkers Consortium last year 

solidified its membership base and launched its first two projects. 

This groundbreaking public-private partnership works to find and 

validate biological markers (biomarkers)—the critical first step in 

understanding disease processes and ultimately preventing, detecting, 

and treating them. 

A biomarker is a biological measurement or set of measurements 

that describes a physiological state. Blood pressure, for example, is a 

widely accepted biomarker for cardiovascular health. Lab tests and 

x-rays look for biomarkers to diagnose specific medical conditions 

or injuries. Biomarkers are also important in assessing the safety and 

effectiveness of drugs and therapies. 

Identifying, evaluating, and utilizing biomarkers can be a complex, 

time-consuming, and costly process—making a collaborative, 

multi-disciplinary approach imperative. The Foundation for NIH is 

uniquely positioned within the biomedical community to create and 

manage such a partnership. Four steering committees focused on 

distinct disease areas—cancer, inflammation and immunity, metabolic 

disorders, and neuroscience—guide the group’s work. Each 

comprises dozens of experts from the public, private, and non-profit 

sectors, academia, and advocacy groups. 

The consortium’s first two projects are designed to determine 

whether a promising imaging technology, FDG-PET, can measure 

the effectiveness of conventional cytotoxic drugs against two types 

of tumors—lymphoma and lung cancer. Conducted by the National 

Cancer Institute (NCI), the studies could have enormous impact on 

patients’ case management and accelerate drug development. 

The foundation so far has raised $6.43 million from nine privatesector 

donors for these projects, while NCI has committed public 

funds and in-kind contributions totaling $3.75 million. Upcoming 

projects will address biomarkers associated with type II diabetes 

and atherothrombosis. Other studies under consideration focus on 

Alzheimer’s disease, metastatic tumors, and rheumatoid arthritis. 

The consortium’s founding members include NIH, Food and 

Drug Administration (FDA), and Pharmaceutical Research and 

Manufacturers of America (PhRMA); other significant partners 

include Centers for Medicare and Medicaid Services (CMS), 

Biotechnology Industry Organization (BIO), and a dozen major 

pharmaceutical companies. 

www.biomarkersconsortium.org 


The Biomarkers Consortium Contributing Membership 

The foundation’s contributing membership program supports consortium operations. To date, 

51 participating organizations (22 companies and 29 non-profit organizations, advocacy groups, 

and trade associations) have contributed more than $2.4 million. 

The Biomarkers Consortium Contributing Members 

Academy of Molecular Imaging 

Advanced Medical Technology Association 

Alliance for Aging Research 

Althea Technologies 

Alzheimer’s Association 

American Association for Cancer Research 

American Cancer Society 

American College of Neuropsychopharmacology 

American Health Assistance Foundation 

American Society for Clinical Pharmacology 

and Therapeutics 

American Society for Therapeutic Radiology 

and Oncology 

American Society of Clinical Oncology 

Association of Clinical Research Organizations 

AstraZeneca LP 

Autism Speaks 

Avalon Pharmaceuticals 

Battelle Memorial Institute 

BG Medicine 

Biotechnology Industry Organization – BIO 

Boehringer-Ingelheim Pharmaceuticals 

Bristol-Myers Squibb 

Digilab Biovision GmbH 

Eli Lilly and Company 

Federation of Clinical Immunology Societies 

GlaxoSmithKline 

GVK Biosciences 

High Q Foundation 

F. Hoffmann-La Roche 

Immune Tolerance Institute 

Ingenuity Systems 

Johnson & Johnson 

Juvenile Diabetes Research Foundation 

Kidney Cancer Association 

The Leukemia and Lymphoma Society 

Luminex Corporation 

Lundbeck 

Lupus Foundation of America 

Lupus Research Institute 

Merck & Co., Inc. 

Merck Serono 

Michael J. Fox Foundation for Parkinson’s Research 

Novartis 

Novo Nordisk 

Pfizer Inc 

Pharmaceutical Research and Manufacturers 

of America – PhRMA 

Polo Ralph Lauren Foundation 

Radiological Society of North America 

Rules-Based Medicine, Inc. 

Society of Nuclear Medicine 

Vanderbilt University 

Wyeth 

Foundation for the National Institutes of Health www.fnih.org | 5

The Foundation for NIH has 

provided an ideal environment 

for public-private partnerships, 

permitting scientists from different sectors to collaborate 

for research that is in the public’s interest. 

—Thomas R. Insel, M.D. 

Director, The National Institute of 

Mental Health at NIH 


Osteorarthritis Initiative 

In 2007, the Osteoarthritis Initiative (OAI) began to 

generate findings in journals and presentations, while it 

continued to release new data and images from its fiveyear 

study on knee health. 

The study, which tracks nearly 5,000 subjects over time, 

aims to increase understanding, and ultimately improve 

treatment of a major cause of disability among Americans. 

The most common type of arthritis, osteoarthritis affects 

more than 15 million people in the United States. By 

2030, 70 million Americans will be 65 years old or older 

and at risk for this progressive disease. 

So far, the initiative has released baseline clinical 

data on all participants, as well as 12- and 18-month 

follow-up data and images on many. When the study 

is complete, the information will document the natural 

progression of the disease and help identify biomarkers 

associated with it, ideally hastening research and therapies. 

The Foundation for NIH facilitated formation of the 

initiative, bringing together seven components of NIH 

and four private-funding partners who have together 

contributed more than $18.5 million. 

All OAI data and images are available to researchers 

worldwide, through the initiative’s web site at 

www.oai.ucsf.edu, along with tools to interpret them. 

So far, almost 750 researchers from 40 different countries 

have registered with the site. Research abstracts 

and findings based on the data have appeared in several 

publications and in presentations before the American 

College of Rheumatology and the Osteoarthritis Research 

Society International. 

CONTRIBUTORS INCLUDE 



Novartis 

Pfizer Inc 

“The Foundation for NIH has been 

and continues to be, critically 

important to the success of the 

Osteoarthritis Initiative that is 

sponsored by many NIH institutes 

and offices as well as industry.” 

—Stephen I. Katz, M.D. 

Director, National Institute of 

Arthritis and Musculoskeletal 

and Skin Diseases at NIH 


ADNI: Alzheimer’s Disease 

Neuroimaging Initiative 

First described more than 100 years ago, Alzheimer’s 

disease has no cure or lasting, effective treatment. More 

than 4 million people in the United States suffer from it 

and its incidence is projected to increase dramatically over 

the next 20 years. 

The goal of the Alzheimer’s Disease Neuroimaging 

Initiative (ADNI) is to alter that prognosis. The NIH’s 

largest public-private partnership on brain research, this 

five-year study tracks normal, mildly cognitively impaired, 

and Alzheimer’s disease brain changes to measure progression 

of the condition. 

The initiative completed enrollment in August 2007. 

Using MRI and PET imaging and laboratory and cognitive 

tests, the study monitors 823 participants over two to 

three years, building a comprehensive database as it goes. 

This catalog will serve as an important public resource 

to spur further research. Already, many of the tools and 

methods developed by the study are fueling efforts in 

Japan, the European Union, and Australia. 

Conducted by the National Institute on Aging (NIA) in 

conjunction with more than a dozen other federal agencies 

and private-sector companies and organizations, this 

$60 million effort has relied on the Foundation for NIH 

to raise nearly $25 million. 

In 2007, additional funds were secured to conduct a 

genome-wide association study and analysis of ADNI 

participants. This effort will provide the most extensive 

and robust dataset of its kind in the Alzheimer’s disease 

field. A second supplement to the study allows for the 

collection of cerebrospinal fluid from participants, while a 

third explores the use of PET and Pittsburg Compound B 

(PIB) as a tool for developing biochemical markers. 

Contributors to adni include 

Alzheimer’s Association GlaxoSmithKline 


Innogenetics 

Bristol-Myers Squibb 

Company 

Cure Alzheimer’s Fund 

Eisai Inc. 

Elan Pharmaceuticals 

Eli Lilly & Company 

GE Healthcare 

Gene Network Sciences 

Institute for the 

Study of Aging 


Novartis 

Pfizer Inc 

Wyeth 

“Working with the Foundation for NIH has made it possible to expand 

the horizons of genome research well beyond what NIH could do alone. 

Everyone agrees that public-private partnerships are critical to our future 

—but the Foundation for NIH makes those a reality!” 

—Francis Collins, M.D., Ph.D. 

Director, National Human Genome 

Research Institute at NIH 


GAIN: Genetic Association 

Information Network 

In 2007, the Genetic Association Information Network 

(GAIN) completed an ambitious program to genotype 

existing research studies in six major common diseases, 

and combine the results with clinical data to create a 

significant new resource for genetic researchers. 

The network’s goal is to help find genetic causes for common 

diseases, and its initial efforts focused on Attention 

Deficit Hyperactivity Disorder, diabetic nepropathy in 

type I diabetes, major depression, psoriasis, schizophrenia, 

and bipolar disorder. 

The resulting data are being deposited in a database 

within the National Library of Medicine at NIH, funded 

by GAIN, for the broad use of the research community. 

By comparing the genetic makeup of healthy people 

with that of people with the disease, scientists should be 

better able to target diagnosis, treatment, and prevention 

strategies. Originators of the initial studies have received 

additional grants to make their own analyses. 

Managed by the Foundation for NIH, GAIN combines 

the resources and expertise of several public and private 

entities to streamline the genetic research process. The 

program’s protocols for protecting participant privacy 

and confidentiality have served as a model for similar 

studies across the scientific community. 

The Foundation for NIH has raised $26 million for the 

network in cash and in-kind resources, primarily from 

Pfizer Inc and Affymetrix, Inc. 

Partners in GAIN include 

Abbott Laboratories 

Affymetrix, Inc. 

Broad Institute of the Massachusetts Institute 

of Technology and Harvard University 

Perlegen Sciences, Inc. 

Pfizer Inc 

GAIN has genotyped over 18,000 samples in six 

major common diseases in less than 18 months. 


The Grand Challenges in Global Health initiative 

brings together scientists around the world to discover 

innovative solutions to the 

greatest global health problems. 

The Gates Foundation is proud to partner with the 

Foundation for NIH to make the initiative a success. 

—Tachi Yamada, M.D. 

President, Global Health Program 

Bill & Melinda Gates Foundation 


GCGH: 

Grand Challenges 

in Global Health 

The Grand Challenges in Global Health (GCGH) initiative was established in 2003 

to address and overcome scientific obstacles to solving the major health challenges 

of the developing world and to create “deliverable technologies”—health tools—that 

are not only effective, but also inexpensive to produce, easy to distribute, and simple 

to use in developing countries. 

A partnership between the Foundation for NIH, the Bill & Melinda Gates 

Foundation, The Wellcome Trust, and the Canadian Institutes of Health 

Research, this $436.6 million initiative funds over 40 projects that variously 

seek to tackle one of 14 major scientific challenges that, if solved, could lead 

to important advances in preventing, treating, and curing diseases of the 

developing world. 

Each year, over 300 scientists meet to review progress, share ideas and forge new 

partnerships to ultimately reduce the technical barriers to improved health in the 

developing world. 

Five years into its work, the initiative is seeing promising progress in understanding 

the basis for severe malaria in children, the development of new insect-control 

measures, the development of new approaches to drug development, the treatment 

of chronic infectious diseases, the improvement of the nutritional value of crops 

and more. 

GCGH CapeTown 

The 2007 GCGH annual meeting was held 

in Capetown, South Africa in conjunction 

with the Keystone Symposium. The Most 

Reverend Bishop Desmond Tutu, Ann 

Veneman, Executive Director of UNICEF, 

and Graça Machel, wife of Nelson Mandela 

and a passionate advocate for human 

rights, spoke on the challenges of global 

health and improving the lives of people in 

the developing world. 


CTC-VIMC: 

Comprehensive T Cell Vaccine 

Immune Monitoring Consortium 

Part of a major international effort to find an AIDS 

vaccine, the Comprehensive T Cell Vaccine Immune 

Monitoring Consortium (CTC-VIMC) works to standardize 

certain laboratory testing practices across clinical 

trials. This is a key step in speeding and simplifying the 

testing of new vaccine candidates. Substantial progress 

was made in 2007. 

The CTC-VIMC is funded by a $33 million, five-year 

grant from the Bill & Melinda Gates Foundation as part 

of the Collaboration for AIDS Vaccine Discovery. It is 

directed by the Vaccine Research Center of the National 

Institute of Allergy and Infectious Diseases (NIAID), and 

is administered by the Foundation for NIH. 

The ability to reliably and consistently measure T Cell 

responses to vaccine candidates is critical to AIDS vaccine 

development. The consortium is creating two procedures 

to do this—initially in four laboratories and then 

expanding to seven others in key international locations. 

This will enable the comparison of results of different 

vaccines from different clinical trials and accelerate the 

development of effective vaccines against HIV. 

“With the continual worldwide emergence and re-emergence of deadly infections 

and their impact on global health, there has never been a greater need for 

innovation, creativity, and partnership among all those seeking to make the 

world a healthier place. We at NIAID are deeply grateful to the Foundation 

for NIH for their efforts in the facilitation of global health research and in 

propagating new ideas to address global health challenges.” 

—Anthony Fauci, M.D. 

Director, National Institute of Allergy 

and Infectious Diseases at NIH 


GHSI: Global Health 

Security Initiative 

The Foundation for NIH was a lead sponsor of the 

Eighth Ministerial Summit of the Global Health Security 

Initiative (GHSI), held for the first time in the United States 

last fall. 

Formed in 2001, the GHSI works to protect public 

health and security on a global scale by strengthening 

preparedness and response to terrorist and health 

threats such as biological, chemical, radiological, and 

nuclear attack and pandemic influenza or other infectious 

disease outbreaks. 

U.S. Health and Human Services Secretary Michael 

O. Leavitt hosted his counterparts from Canada, France, 

Germany, Italy, Japan, Mexico, and the United Kingdom, 

as well as from the European Union and the World Health 

Organization at the Bethesda campus of the NIH. 

The summit featured three days of policy and technical 

meetings, focused especially around laboratory networks, 

radiological and nuclear threats, chemical events, risk 

management and communications, and pandemic influenza. 

The foundation organized several high-level panel 

discussions, which included speakers such as Chairman 

Charles A. Sanders, M.D., who spoke about public-private 

partnerships, and Director of Science Daniel J. Carucci, 

M.D., Ph.D., who spoke about the Grand Challenges in 

Global Health Initiative. 

Other summit sponsors include 

AERAS Global TB Vaccine Foundation 


BIO – Biotechnology Industry Organization 

Elusys Therapeutics, Inc. 

Pfizer Inc 

PhRMA – Pharmaceutical Research 

Manufacturers of America 

Michael O. Leavitt, 

Secretary, HHS 

Elias A. Zerhouni, M.D., 

Director, NIH 

Amy McGuire Porter, 

Executive Director, 

Foundation for NIH 

Below are the GHSI Ministers 

Infectious diseases, poor maternal and newborn 

health, and malnutrition are responsible for 

nearly half of all deaths in the developing world, 

many of them preventable. 


Actions taken at the 2007 Collaborative Summit on Breast Cancer Research 

are resulting in greater levels of collaboration and 

cooperation among non-profit groups and 

advocacy organizations working in the field; 

not only altering the ways in which non-profits interact with one another, 

but also sparking new and necessary conversations with government and 

industry. The Foundation for NIH played a critical role, providing both 

intellect and effort in organizing a successful summit, but most importantly 

serving as an impartial, ‘neutral’ convener, and sometimes arbiter, to pull 

these key groups together. 

—Marc Hurlbert, Ph.D. 

Director, Avon Foundation 

Breast Cancer Crusade 


Collaborative Summit on 

Breast Cancer Research 

Surveying the array of funders, researchers, advocates, pharmaceutical industry 

representatives, regulators, and policymakers engaged in the fight against breast cancer, 

the Avon Foundation turned to the Foundation for NIH to convene a summit to 

foster collaboration among these entities. 

The Foundation for NIH brought together leaders from 27 funding organizations 

and advocacy groups and a host of other experts at a productive meeting in November 

with special keynote speaker Paula Zahn. Despite their varying approaches, philosophies, 

and programs, participants engaged in frank and open dialogue about 

how best to advance toward their ultimate common goal of eradicating breast 

cancer. There was consensus on the need to better utilize resources—by identifying 

funding gaps and opportunities, and eliminating barriers and redundancies. 

Outcomes included the formation of a “National Breast Cancer Planning 

Committee” to periodically review the breast cancer landscape and national 

agenda, a common database on grant awards, and a public report about how 

donations are used. 

“This Summit was a critical step toward 

identifying, analyzing, and eventually 

overcoming all the barriers that stand 

between where we are now and the 

eradication of breast cancer. The 

researchers of our nation and the world 

Paula Zahn, 

Keynote Speaker 

The Honorable 

John Edward Porter, 

Vice Chairman, 


General Session 

are counting on the united dedication of 

organizations, governments, corporations, 

and individuals to this mission.” 

Summit Organizers: 

National 

Cancer 

Institute 

T h e 

Breast 

Cancer 

Research 

Foundation 

—Larry Norton, M.D. 

Deputy Physician-in-Chief, 

Breast Cancer Programs at 

Memorial Sloan-Kettering 

Cancer Center 

PANTONE 

287 (50%TINT) 

PANTONE 

BLACK 

CMYK: 50,34.5,0,5.5 


AVON-NCI Progress for 

Patients Awards Program 

Now in its sixth year, the Avon-NCI Progress for Patients Awards Program has 

made a significant impact on breast cancer research, accelerating the movement 

of pre-clinical discoveries to application in patients, and fostering collaborative 

efforts that optimize resources and efficiencies. 

A $33 million partnership between the Avon Foundation, the National 

Cancer Institute, and the Foundation for NIH, the program has funded 

59 projects that span the full spectrum of interventions in the prevention, 

risk assessment, diagnosis, and treatment of breast cancer, including imaging, 

pathology, radiation oncology, drug development, and biomarker analysis. 

Since its inception, the partnership has focused on attracting young scientists 

to breast cancer research and supporting studies that include minority 

and under-served populations. To build on the collaborative momentum the 

program has engendered and carry it forward, the participating scientists and 

doctors formed a Translational Breast Cancer Consortium to provide a formalized 

structure for future cooperation. 

Even though the rate of cancer mortality 

continues to drop, cancer still remains a leading 

cause of death, second only to heart disease. 


Targeted Cancer 

Therapies Tutorials 

Targeted therapies have been 

developed for a number of 

cancers, and new therapies are 

in testing. The hope is that these 

targeted therapies will eventually 

allow certain cancers to be 

treated as chronic conditions and 

that, based on a patient’s specific 

genetic make-up, physicians will 

know which patients will respond 

best to which targeted treatment. 

With the help of Genentech, the Foundation for NIH is funding creation of 

four tutorials on targeted cancer therapies. The animated tools, designed for use 

by oncologists, oncology nurses, and other health professionals, will be posted 

on the National Cancer Institute’s web site at www.cancer.gov. 

Targeted therapies are drugs that block the growth and spread of cancer by 

interfering with specific molecules within a cancer cell. Most targeted therapies 

are still in the testing stages, but some are already in use. Because they focus 

only on cancerous cell changes, they have the potential to be more effective and 

produce fewer side effects than existing treatments. 

Physicians will use the tutorials to explain and review treatment options with 

their patients. The tutorials will explain what targeted therapies are, provide 

information on clinical trials, encourage participation in the trials, and establish 

targeted therapies as a standard of care. 

The first tutorial will provide an overview of targeted therapies; the others 

will each focus on a specific type of cancer and its targeted therapy: breast, lung, 

or colon cancer. 

Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) 

measures efficient glucose utilization and can provide an early indication of 

response to therapy. The FDG-PET lung and lymphoma projects being implemented 

by The Biomarkers Consortium are anticipated to be the first in a series of initiatives to 

improve the development of cancer therapies and the outcomes for cancer patients using 

FDG-PET as a surrogate endpoint in the progression of cancer. 


The National Institute of Aging (NIA) continues its close and 

productive collaboration with our partners at the McKnight 

Brain Research Foundation (MBRF) and the Foundation for 

NIH. In October, the MBRF helped bring together the nation’s 

top scientists for a ground-breaking summit on cognitiveaging 

research. They identified critical areas 

for future investigation, and the MBRF 

is committed to collaborating with NIA 

in supporting such research. We anticipate that 

this ongoing partnership will lead to important advances and 

improvements in cognition in older Americans. 

—Richard J. Hodes, M.D. 

Director, National Institute of 

Aging at NIH 


Measures for Clinical Trials of 

Treatment of Cognition 

In 2007, the Foundation for NIH secured $1.6 million 

in funding from eight industry partners to launch the 

Measures for Clinical Trials of Treatment of Cognition 

project. This partnership supports a National Institute 

of Mental Health (NIMH) initiative to develop a set of 

tools that can assess the effectiveness of drugs used to 

treat schizophrenia. 

The initiative will also translate and adapt a series of 

tests to measure cognitive performance. This Matrix 

Consensus Cognitive Battery will be standardized for use 

in international clinical trials. 

Schizophrenia is a chronic, severe brain disorder that 

affects over one percent of the U.S. population. Because 

many sufferers have difficulty holding a job or caring 

for themselves, the burden on their families and society 

is significant. Current treatments fall short of relieving 

many symptoms. 

NIMH manages the partnership, while the foundation 

coordinates a Scientific Board comprising representatives 

from NIH, FDA, industry, academia, and the 

advocacy community. 

Contributors to the Measures 

For Clinical Trials of Treatment 

of Cognition include 

AstraZeneca 

Bristol-Myers Squibb Company 



Lundbeck 

Ortho-McNeil Janssen 

Pfizer Inc 

sanofi-aventis 

Cognitive Aging Summit 

In a partnership with the McKnight Brain Research Foundation (MBRF), the National Institute 

on Aging (NIA) convened a Cognitive Aging Summit in October to further the understanding of 

cognitive and behavioral changes associated with normal aging. Facilitated by the Foundation 

for NIH, the summit assembled experts from a variety of scientific disciplines to discuss the 

latest advances, explore new avenues for potential research, and raise awareness about the 

importance and value of research in the process of learning and in the maintenance of cognitive 

health with age. 

Summit participants identified research opportunities that could be pursued through future 

partnerships, and a program of research grants to be jointly funded by NIA and MBRF was 

approved and is scheduled to begin in 2009. Each organization has committed at least $1 million 

per year for a period of five years in support of this important research partnership. 


CRTP: Clinical Research 

Training Program 

After a decade in action, the Clinical Research Training Program (CRTP) for 

medical and dental students has become a highly successful, widely recognized 

model for fellowship programs around the country. As many as 30 students 

a year come to the NIH campus for an intensive 12-month clinical or translational 

research project. The participants, known as fellows, are paired with 

senior NIH physician-scientist mentors on projects matched to their interests. 

Fellows attend clinics, see patients in wards, and participate in interactive 

group forums with leading NIH researchers and one another. They work 

with a principal investigator in both the laboratory and at the bedside to 

learn about translational research, the transformation of basic research into 

patient therapies. 

The fellowships, equally funded by Pfizer Inc and NIH, may be 

extended for a second 12 months, depending on the support of the sponsoring 

NIH institute, availability of funds, and the student’s home institution. 

CRTP 10-YeaR Reunion— 

March 2007 

With the aim of cementing the long-term 

relationship between NIH and CRTP fellows, the 

Foundation for NIH organized a reunion for all 

program alumni. The fellows represent some of 

the nation’s best and brightest young physicians 

and scientists whose careers have been shaped 

significantly by their experience at NIH. 

The reunion offered rich opportunities for 

interaction amongst all fellows, their mentors, 

and advisers. Panels led by distinguished NIH 

scientists and a day-long seminar highlighted 

recent developments in clinical research at NIH 

and throughout the nation. 

“Pfizer’s partnership with the NIH is based on mutual goals outlined by the Roadmap— 

innovation and excellence in science. Our support of the CRTP over the past 10 years 

advances our mutual goal of developing the clinical researchers of the future. We are also 

excited about participating in the biomarker and genomic collaborations which are key 

to unlocking new scientific discoveries.” 

—Joseph M. Feczko, M.D. 

Chief Medical Officer, Pfizer Inc 

Bernard Osher Foundation/NCCAM Practitioner Research 

Career Development Award 

In September 2007, Weidong Lu, MB, MPH, LicAc, was named the first recipient of the Bernard Osher Foundation/NCCAM 

Practitioner Research Career Development Award. Dr. Lu is a licensed acupuncturist who also holds a clinical degree from 

Zhejiang College of Traditional Chinese Medicine in China, equivalent to a U.S. clinical doctorate. 

The award represents a seven-year partnership between the Foundation for NIH, The Bernard Osher Foundation, and the 

National Center for Complementary and Alternative Medicine. Up to three awardees may be selected each year. 

This award will give Dr. Lu time to focus his research skills through course work, tutorials with his mentors, and execution of 

two of his own pilot research projects to test the effectiveness of acupuncture for head and neck cancer patients who develop 

dysphagia (trouble swallowing) after chemoradiation therapy. His long-term goal is to become an established independent 

research investigator in complementary and alternative medicine. 


Foundation for NIH Supports 

Numerous Programs & Events 

The Foundation for NIH supports many more programs and events through fundraising, management, 

and facilitation, including: 

Research Programs 

Adolescent and Young Adult Oncology 

Progress Review Group 

ADNI Cerebral Spinal Fluid Project 

ADNI Genotyping Analysis 

ADNI PET PIB Supplement 

Best Pharmaceuticals for Children Fund 

Biotechnology Resource for Innovation 

and Development in Genomedicine 

Cooperative Breast Cancer Tissue Resource 

Fatty Acid Methyl Esters 

Training/Youth/Education 

Programs 

Action to Cure Kidney Cancer Fellowship 

Clinical Investigator Student Training Forum 

National Leadership Workshop on Mentoring 

Women in Biomedical Careers 

Neuoendrocine Tumor-Carcinoid Summit Workshop 

Public Health Informatics Training Program 

Women’s Health Clinical Fellowship 

Women’s Health Postdoctoral Fellowship 

Frequent Hemodialysis 

Head-Off Environmental Asthma in Louisiana 

Human Papilloma Virus Clinical Trial 

Imaging Database Resources Initiative 

Observational Medical Outcomes Partnership 

PATH Youth Program: HIV/AIDS in Adolescents 

Schizophrenia Metabolic Initiative 

Toxicity Study of Buprenorphine/Naloxone 

Clinique Women’s Health Summer Research Internships 

In an effort to encourage young women and minority students to pursue careers in nursing and 

science, last year the Foundation for NIH awarded the first three Clinique Women’s Health Summer 

Research Internships. The eight- to 10-week intensive biomedical internships, funded by cosmetic firm 

Clinique, were offered to undergraduate students interested in skin cancer research or dermatology. 

The awardees were: Neha Agarwal, Jean Suh, and Laurel Cummings. 

At the start of the program, the interns visited Clinique headquarters in New York City where each was 

presented with a personalized lab coat. At the conclusion of the summer, they presented their research 

at a Foundation for NIH reception in their honor. 

Clinique Internship Program 

organizers and awardees 


Since it opened in 2005, the Edmond J. Safra Family 

Lodge has been a welcoming refuge, free of charge, 

for more than 38,000 family caregivers from around 

the world. Located on the NIH campus, just steps 

away from the Clinical Center, the Edmond J. Safra 

Family Lodge offers a home for families and loved 

ones of adult patients who are participating in 

clinical trials and receiving care. Gifts of all sizes 

play an essential role in this vital endeavor on behalf 

of those with serious illness and disease. 

Award-winning composer and musician Marvin 

Hamlisch returned for his third annual performance at 

the Edmond J. Safra Family Lodge Holiday Concert in 

December. Hamlisch’s connection to the Edmond J. 

Safra Family Lodge stems from his long friendship with 

Mrs. Lily Safra, who, along with the Edmond J. Safra 

Philanthropic Foundation, provided the principal 

private funding for its construction. 

We know that when illness afflicts one person, an entire family can 

suffer. The mission of the Edmond J. Safra Family Lodge is to give 

those families a place to remain resilient and together. 

Edmond J. Safra Family Lodge 

—Mrs. Lily Safra 

Chairman, 

Edmond J. Safra Philanthropic Foundation 

Edmond J. Safra 


Endowments at the 


Through endowment gifts, donors ensure perpetual support for a variety of research and educational 

initiatives at the Foundation for NIH. The annual investment income generated by an endowment 

fund covers program expenses, while the principal remains intact to ensure future funding. 

Edna Williams Curl and Myron R. Curl 

Endowment 

The Edna Williams Curl and Myron R. Curl Endowment, 

established in 2007, supports multiple sclerosis research at the 

National Institutes of Health. 

John Laws Decker Memorial Fund 

During his lifetime, Dr. John Laws Decker strived to connect 

research communities around the world to exchange information 

and promote the acceleration of important scientific research. 

Mrs. Lucille Decker and the Decker family created the John Laws 

Decker Memorial Fund in 2003 to establish an annual lecture 

memorializing his dedication to education and communication 

about science. The endowment and the lecture it supports stand 

as a permanent and fitting tribute to Dr. Decker’s memory. 

John I. and Elaine K. Gallin Endowment 

The Gallin Endowment provides amenities at the Edmond J. Safra 

Family Lodge for family members who accompany loved ones 

participating in clinical trials at the NIH campus in Bethesda, 

MD. The endowment was established in 1999 in anticipation of 

the opening of the Edmond J. Safra Family Lodge in 2005. 

GlaxoSmithKline Endowment Fund 

The GlaxoSmithKline Endowment supports programs and 

activities for families staying at the Edmond J. Safra Family 

Lodge, including services that help residents stay in touch with 

employers and loved ones. 

Sallie Rosen Kaplan Fund for Women 

Scientists in Cancer Research 

The Kaplan Fund, established in 2000, provides annual support 

for the Sallie Rosen Kaplan Fellowships for Women Scientists in 

Cancer Research. These post-doctoral fellowship awards are given 

annually to one or more outstanding woman scientists at the 

National Cancer Institute. 

Robert Whitney Newcomb Memorial Fund 

This permanent fund was established in 2000 by the Newcomb 

family. Through a charitable remainder trust, the Newcomb 

Memorial Fund endows an annual lecture in neuroscience as well 

as internships for high school students at the National Institute of 

Neurological Disorders and Stroke (NINDS). 

Norman P. Salzman Memorial Fund 

Dr. Norman Salzman’s family, colleagues, and friends remember 

the legacy of this noted pioneer in molecular biology through 

contributions to the Salzman Memorial Fund, which supports 

an annual symposium and award in virology. The half-day 

symposium addresses key topics in virology and immunology 

and is attended each year by researchers, medical students, and 

health professionals. 

Stephen E. Straus Endowment 

Established by Bernard and Barbro Osher in 2006 in honor of 

Dr. Straus, this endowment funds the Stephen E. Straus Award, 

recognizing the outstanding research accomplishments of a 

young scientist in the field of complementary and alternative or 

integrative medicine. 

Harry and Jeanette Weinberg Endowment at 

the Edmond J. Safra Family Lodge 

The Weinberg Endowment was created in 2002 and supports 

the operation and maintenance of the Edmond J. Safra Family 

Lodge—ensuring that guests are provided a comfortable home 

away from home for years to come. 

NormaN P. Salzman Memorial Award 

Two researchers were honored with the 2007 Norman P. Salzman Memorial Award. Adriano Boasso (mentored by Gene M. Shearer) 

was the first awardee. Audray Harris, the second awardee (mentored by Dr. Alasdair C. Steven) received a special recognition. 

The memorial serves as a living legacy for Norman P. Salzman, who was a mentor to many young scientists. It is awarded to an 

outstanding post-doctoral fellow and his or her mentor for innovative and creative research, and it is a model for encouraging and 

recognizing scientific discovery. 

More than 150 researchers, post-doctoral fellows, medical students, and health professionals attended the presentation and related 

symposium. The Foundation for NIH deeply appreciates Mrs. Lenore Salzman’s vision and leadership and thanks her for the role she 

has played in the program’s outstanding growth. 


Financial Summary December 31, 2007 and 2006 

REVENUE AND SUPPORT 2007 2006 

Contributions $ 21,575,175 $35,825,823 

Grants 34,822,284 32,863,346 

Administrative Fee 349,698 632,545 

Government Appropriations 500,000 500,000 

Investment Earnings 8,207,287 9,302,533 

In-Kind Contributions 23,288,249 296,522 

Donated Services 192,839 338,571 

Total Revenue and Support 88,935,532 79,759,340 

EXPENSES AND CHANGES IN NET ASSETS 

Program Services 

Fellowships and Training Programs 710,349 897,745 

Memorials, Awards and Events 919,593 532,798 

Capital Projects 24,802 69,047 

Research Partnerships 80,328,753 54,927,989 

Total Program Services 81,983,497 56,427,579 

Supporting Services 

Management and General 2,789,382 1,877,098 

Fundraising 164,476 180,803 

Total Supporting Services 2,953,858 2,057,901 

Total Expenses 84,937,355 58,485,480 

Change in Net Assets 3,998,177 21,273,860 

Net Assets Beginning of Year 47,525,215 26,251,355 

Net Assets End of Year $51,523,392 $47,525,215 

The foundation’s complete audited financial statements with an unqualified opinion by 

Goodman & Company, LLP are available on request at www.fnih.org. 


2007 REVENUES 

Contributions 24% 

Grants 40% 

Other Revenue 27% Investment Earnings 9% 

2007 EXPENSES 

Research Partnerships 95% 

Management and Fundraising 3% 

Education and Events 2% 


Donors by Recognition Group 

The Foundation for NIH enables the private sector to support research 

and scientific discovery at NIH in many ways. Corporations, private 

foundations, associations, individual philanthropists, and the general 

public — everyone interested in improving human health — can 

become a partner in particular initiatives by making a restricted gift or 

by contributing to support NIH’s work in general. As outlined in the 

preceding pages, restricted gifts support many and varied initiatives, 

including complex biomedical research programs; educational efforts 

such as fellowships, lectures, and symposia, that train scientists and help 

them build their careers; and specific laboratories or areas of scientific 

research at NIH. Unrestricted gifts support core operations and enable the 

foundation to develop emerging program areas and new partnerships. 

The foundation is very efficient in managing the private sector’s 

investment. Of every dollar spent by the foundation, 97 cents is used to 

support programs, and just 3 cents for administration and fund-raising. 

Indeed, in 1997, the foundation was the top-rated charity among 

the 593 health charities rated by Charity Navigator, which evaluates 

organizational efficiency, capacity, and overall financial health, and the 

third highest rated among all 5,327 non-profits evaluated. 

The following donors and partners made gifts or pledges during 

the 2007 fiscal year (January 1–December 31, 2007). 

The Foundation for NIH makes every attempt to list donors according to 

their wishes. Please call 301-594-9565 if you have questions. 

LIFETIME GIVING SOCIETY 

The Lifetime Giving Society recognizes 

individuals for their generous commitments 

of $100,000 or more overtime. 

Bruce & Martha Atwater 

The Honorable & 

Mrs. William McCormick Blair, Jr. 

Ann Lurie 

Dr. & Mrs. Paul M. Montrone 

Bob & Sally Newcomb 

Bernard & Barbro Osher 

Mrs. Lily Safra 

Dr. & Mrs. Charles A. Sanders 

Jane M. Sayer, Ph.D. 

Mr. & Mrs. Eric Weinmann 

DISCOVERY SOCIETY 

The Foundation for NIH acknowledges 

individuals who have supported our 

programs with a major gift in 2007 as 

members of the Discovery Society. 

$100,000+ 

Bruce & Martha Atwter 

Ann Lurie 


$50,000–$99,999 



$25,000–$49,999 



Buffy & William Cafritz 

Mr. Russell L. Carson 

Martin J. Murphy, Jr., Ph.D. 

Maha Sallam, Ph.D. 

Lenore R. Salzman 



Mary Weinmann in Honor of 


$10,000–$24,999 

Paula and Bill Bradley 

Mrs. Cyrena Gouge 

Mr. & Mrs. Hermen Greenberg 

Susanne O’Neill 

Jillian Sackler, D.B.E. 

Dr. Ellen V. Sigal & 

Mr. Gerald R. Sigal 

$5,000–$9,999 

Anonymous 

Luther W. Brady, M.D. 

Mark D. Ein 

John I. Gallin, M.D. & 

Elaine K. Gallin, Ph.D. 

Ms. Gail Newcomb & 

Mr. Ted Manley 

Dr. & Mrs. Steven M. Paul 

Solomon & Elaine Snyder 

Stephen & Nina Solarz 

E. Bannan & Francis Swanson 

$2,500–$4,999 

Dr. & Mrs. Paul Berg 

Mr. & Mrs. Robert P. Draim 

Anthony S. Fauci, M.D. 

Alexis Gregory 

Mrs. Calvin D. Linton 

Matthew W. O’Neill 

Amy & John Porter 

Daniel Shapiro & Agnes Gund 

Dr. & Mrs. Stephen P. Spielberg 

Dr. & Mrs. Patrick C. Walsh 

$1,000–$2,499 

Robert Armstrong 

Jeff & Marie Baker 

Jill H. Barr 

Samuel & Gail Broder 

Mr. Ross Chambers 

Lucille M. Decker 

Cynthia Dunbar & Charles Cerf 

Ronald G. Evens, M.D. 

Nicholas & Jacqueline Ferriter 

Mrs. Pamela Fisher 

Mr. Thomas H. Hassall 

Eric & Amanda Hirshik 

Daniel Khodorkovsky 

Caroline A. Kovac, Ph.D. 

Sherry Lansing 

Donna & Craig Leidersdorf 

Fred & Mary McVean 

Duy Tam & Gisele Nguyen 

Mr. Khanh Nguyen 

Robert & Barbara Roberts 

Richard Scarfo & Patrick Myers 

Dr. Douglas Shander 

John & Marcia Shooshan 

Mr. & Mrs. Albert H. Small, Sr. 

Mark Anthony Spiteri 

Staff of the Foundation for the 

National Institutes of Health 

$500–$999 

Mr. Caleb Amir 

Mr. Jeffrey Anker 

Raymond Bahor & 

Michael Mahoney 

Mr. Roger Bitterman 

Yank D. Coble, Jr., M.D. 

Mrs. Michael K. Deaver 

Margaret B. Eastman 

Ms. Loree Elton 

James M. Felser, M.D. 

Drs. David E. Golan & 

Laura C. Green 

Lee Hall & Mary Frances Cotch 

Mr. Michael M. Hash 

Michael M. Kaback, M.D. 

Steven A. Kradjian 

Joseph Boyd Martin, M.D., Ph.D. 

Janet M. Mattson 

Greg C. & Holly H. McLendon 

Philip A. Pizzo, M.D. 

Ms. Lisa Potetz 

Charles R. Pucie 

Katherine & Mark Read 

Dr. & Mrs. Gregory H. Reaman 

Mr. David Rush 

A. Roger Tsai, M.D. 

Mrs. Henry P. Wheeler 

Mr. Paul Wilmot 

Mr. Robert E. Young 

LEGACY SOCIETY 

The Legacy Society honors those who 

have directed their support for biomedical 

research through a planned gift to the 

Foundation for NIH. 



Patricia & Kenneth Kohlen 

Drs. Zell & Emily Kravinsky 


ENDURING FRIENDS 

The Foundation for NIH recognizes 

those who have supported the foundation 

for five years or more. 

Gary & Sharon Barbarash 




Mark D. Ein 


Peggy & John Gerlacher 

Steve Jacobs, O.D., M.A. 

Dr. Thomas J. Kennedy, Jr. 



Gerald J. & Elizabeth A. Nissen 

Suzanne & Bernard Paley 

Amy & John Porter 





Dr. Ellen V. Sigal & 

Mr. Gerald R. Sigal 



Juli Staiano & Marc Washington 


Stuart H. Yuspa, M.D. 

Mr. & Mrs. Eric Weinmann 

CORPORATE MEMBERS 

Corporate members are key partners in 

furthering medical research to benefit 

people worldwide and ensure the health 

and well-being of employees, clients, and 

the communities that members serve. 

Chroma Technology Corporation 

SunTrust Banks, Inc. 

Zimmer, Gunsul, Frasca 

Architects LLP 


Donors 

$5,000,000+ 


Pfizer Inc 

$1,000,000+ 

Affymetrix, Inc. 


Avon Foundation 

Bristol-Myers Squibb Company 

Broad Institute 



Novartis 

Perlegen Sciences, Inc. 

Pharmaceutical Research & Manufacturers 

of America 

Wyeth 

$500,000–$999,999 

Alzheimer’s Association 

Amgen Inc. 

Genentech, Inc. 


Johnson & Johnson 

Merck Childhood Asthma Network, Inc. 

$100,000–$499,999 

Boehringer Ingelheim Pharmaceuticals, Inc. 

Breast Cancer Research Foundation 

Cure Alzheimer’s Fund 

CVS Caremark Charitable Trust 

Eisai Inc. 

Elan Pharmaceuticals 

GE Healthcare 

Lundbeck 

Ann Lurie 


Ortho–McNeil Janssen 

sanofi-aventis 

$50,000–$99,999 

Anonymous 

Battelle Memorial Institute 

Biotechnology Industry Organization 

Boehringer Ingelheim Cares Foundation, Inc. 

The Edna Williams Curl & Myron R. Curl Fund 

of the Cumberland Community Foundation 

Innogenetics 


Penates Foundation 


The Edmond J. Safra Philanthropic Foundation 

Solvay Pharmaceuticals, Inc. 

The University of Southern Mississippi 

$25,000–$49,999 



Buffy & William Cafritz 

Russell L. Carson 

Clinique Laboratories LLC 

Dell Inc. 

GlaxoSmithKline Biologicals 


in Honor of Dr. John Niederhuber 

Maha Sallam, Ph.D. 




Sigma-Tau Pharmaceuticals, Inc. 

Mary Weinmann in Honor of 


$10,000–$24,999 

Anonymous 

Action to Cure Kidney Cancer 

Aeras Global TB Vaccine Foundation 

American Society of Clinical Oncology 

AMS Foundation for the Arts, Sciences 

& Humanities 

Autism Speaks 

Paula and Bill Bradley 

in Memory of Richard A. Lauderbaugh 

Burroughs Wellcome Fund 

Dean O’Neill Irrevocable Living Trust 

Doris Duke Charitable Foundation 

Gene Network Sciences 

Mrs. Cyrena Gouge 

Mr. & Mrs. Hermen Greenberg 

Luminex Corporation 

Jillian Sackler, D.B.E. 

Dr. Ellen V. Sigal & Mr. Gerald R. Sigal 

The Commonwealth Fund 

The Monica & Hermen Greenberg Foundation 

World Health Organization — AFRO 

$1,000–$9,999 

Anonymous 

Abcam, Inc. 

Academy of Molecular Imaging 

Advanced Medical Technology Association 

Albert & Lillian Small Foundation 

Alliance for Aging Research 

Althea Technologies 

American Association for Cancer Research 

American Cancer Society 

American College of 

Neuropsychopharmacology 

SAKS JANDEL fundraiser 

The Foundation for NIH was the focus 

charity at the annual Saks Jandel holiday 

brunch and fashion show. Peter Marx, 

president and CEO of the upscale boutique, 

generously donated 10 percent of all sales 

to the foundation. The show, chaired by 

Mrs. William McCormick Blair, Jr., Mrs. 

William N. Cafritz, and Mrs. Evan Jones, 

featured stunning designs from Valentino’s 

final collection. The runway was lined with 

loyal Saks Jandel customers and a veritable 

who’s who of Washington, DC’s social circles. 

American Health Assistance Foundation 

American Society for Clinical Pharmacology 

& Therapeutics 

American Society for Therapeutic Radiation 

& Oncology 

Robert Armstrong 

Association of Clinical Research Organizations 

Avalon Pharmaceuticals 

Jeff & Marie Baker 

Jill H. Barr 

Dr. & Mrs. Paul Berg 

BG Medicine 

Biospherix, LTD 



Capital Area Carcinoid Survivors 

Carcinoid Cancer Foundation, Inc. 

Caring for Carcinoid Foundation 

Ross Chambers 

Chroma Technology Corporation 

Citigroup Foundation 

Community Foundation for the 

National Capital Region 

Covidien 

Cytori Therapeutics, Inc. 

Lucille M. Decker 

Digilab Biovision GmbH 

Mr. & Mrs. Robert P. Draim 

Cynthia Dunbar & Charles Cerf 

Mark D. Ein 

Ellen Shaw Foundation for Patient Comfort 

Elusys Therapeutics, Inc. 


Donors 

Ronald G. Evens, M.D. 


Federation of Clinical Immunology Societies 

Nicholas & Jacqueline Ferriter 

Mrs. Pamela Fisher in Memory of Alvan Fisher 

John I. Gallin, M.D. & Elaine K. Gallin, Ph.D. 

GenVec, Inc. 

Global Impact Combined Federal Campaign 

Alexis Gregory 

GVK BIOSciences 

Harcourt, Inc. 

Thomas H. Hassall 

Health Policy Alternatives, Inc. 


High Q Foundation 

Eric & Amanda Hirshik 

Immune Tolerance Institute, Inc. 

Ingenuity Systems 

Ipsen 

IQ Solutions 

James S. Kemper Foundation 

Daniel Khodorkovsky 

Kidney Cancer Association 


Sherry Lansing 

Donna & Craig Leidersdorf 


Log Sec Corporation 

Lupus Foundation of America 

Lupus Research Institute 

March of Dimes Birth Defects Foundation 

Mars, Incorporated 

Fred & Mary McVean 

Medtronic, Inc. 

MG Biotherapeutics, LLC 

Michael J. Fox Foundation for 

Parkinson’s Research 

Millipore Corporation 

Molecular Insight Pharmaceuticals, Inc. 

Nadel Trading Corporation 

in Memory of Tracy Nadel 

Network For Good 

Ms. Gail Newcomb & Mr. Ted Manley 

Duy Tam & Gisele Nguyen 

in Memory of Khiem Duy Nguyen 

Khanh Nguyen 


Matthew W. O’Neill 

Dr. & Mrs. Steven M. Paul 

Polo Ralph Lauren Foundation 

John & Amy Porter 

Radiological Society of North America 

RegeneRx Biopharmaceuticals, Inc. 

Robert & Barbara Roberts 

in Memory of Dr. Anita Roberts 

Rules Based Medicine, Inc. 

SAIC-Frederick, Inc. 

sanofi pasteur 

Richard Scarfo & Patrick Myers 

Dr. Douglas Shander 

Daniel Shapiro & Agnes Gund 

John & Marcia Shooshan 


Mr. & Mrs. Albert H. Small, Sr. 


Stephen & Nina Solarz 


Mark Anthony Spiteri 

SunTrust Banks, Inc. 

E. Bannan Swanson 

Frances Swanson 

Tercica, Inc. 

Thoren Caging Systems 

Vanderbilt University 

Wafergen Bio Systems, Inc. 

Dr. & Mrs. Patrick C. Walsh 

$250–$999 

Anonymous (3) 

American College of Radiology Association 


Caleb Amir 

Jeffrey Anker 

Raymond Bahor & Michael Mahoney 

in Honor of Mrs. William McCormick Blair, Jr. 

Drs. Carl C. Baker & Susan R. Haynes 

Gary & Sharon Barbarash 

Roger Bitterman 

Joan Blank 

Walter & Jane Brandt 

Raymond Clement 

Yank D. Coble, Jr., M.D. 

Mrs. Michael K. Deaver 

Sandra Delusque 

Jeffrey Draim 

Margaret B. Eastman 

Catherine Elliott-Rostykus & 

Walter G. Rostykus 

Loree Elton 

Federation of American Hospitals 


James M. Felser, M.D. 

Stanley Geller 

Peggy & John Gerlacher 

Drs. David E. Golan & Laura C. Green 

Dr. & Mrs. Stuart Handwerger 

Joe W. Harris 

Mrs. Carolyn Hartman 

Mr. Michael M. Hash 


James G. Davis Construction Corporation 


JM Zell Partners, LTD 


Brock T. Jolly 

Michael M. Kaback, M.D. 

Harry & Florence Katrivanos 

John Kennedy 

Steven A. Kradjian 

Jody Kris 

Joseph Boyd Martin, M.D., Ph.D. 

Janet M. Mattson, NCMA Chapter President 

Cherry McLaughlin 


Frank L. Meyskens, Jr., M.D. 

Mr. & Mrs. Roger A. Michaels 

M. Janis Mullaney 

Shawn Neil & Thomas Griffiths 

Gerald J. & Elizabeth A. Nissen 

Robert & Judy Norman 

Dr. & Mrs. Frederick W. Parker III 

Scott Parmalee 

Vladimir Pavlovic 

Stephen & Mary Peth 

Stuart B. Phillips, M.D. 

Mitchell Pines in Honor of Nancy Bravman 


Raymond Poissant 

Lisa Potetz 


Dr. Joy Pretcher in Honor of Bunny Eiseman 


Benjamin & Lela Rawson 

RBS Greenwich Capital Foundation, Inc. 

Katherine & Mark Read 

Dr. & Mrs. Gregory H. Reaman 

Barbara Rimer 

Robert & Marjorie Rosenberg 

David Rush 

James & Suzanne Ryan 

Howard K. & Ethel L. Schachman 

Richard & Cynthia Schilsky 

Martin Simek 


Mary R. Sirene 

Anthony Tassone 

A. Roger Tsai, M.D. 

Julie A. Tune 

Mr. & Mrs. William Tworek 

Thomas E. Wellems, M.D., Ph.D. 


Paul Wilmot 

Ryuzo & Hiroko Yanagimachi 

Robert E. Young 


Donors 

$100–$249 

Anonymous (4) 

The Acosta Family in Memory of Gloria Price 

Bob & Miriam Adelstein 

Dr. Bernard W. Agranoff 

Allan Agustin in Honor of Gregory Austin, 

Triumfante Agustin, Robert Lott & 

William Tamayo 

Robert & Audrey Aldrich 

Tony & Kristin Altar 

Elena A. Alvarez 


Ellsworth & Nancy Alvord 

Mary Kay Arbogast 

Drs. Bryan & Donna Arling 

Peter Aronson & Marie Landry 

Michael Assenza 

Richard H. Aster 

Jack D. Barchas, M.D. & 

Rosemary A. Stevens, Ph.D. 

Clare Barrow in Memory of Fred Sisson 

Andrew Bonasera 

Dr. & Mrs. Stephen L. Bradford 

in Memory of Erika NeilLeland W. Briggle 

Mrs. Mary K. Burton 

in Memory of Kenneth Adams 

California Association of Hospitals & Health 

Systems in Memory of Richard A. Lauderbaugh 

William & Martha Campbell 

John & Sally Carter 

in Memory of Adam J. Berry 

Daniel Carucci, M.D., Ph.D. 

Chestnut Hill College 

Thomas G. Cody 

Anthony & Marcia Coe 


C. Norman & Karolynn Coleman 

Peter Crawford 

John Crump 


Richard Curtin 

Glenda & T.S. Dayhoff 

in Memory of Loretta M. Orndorff 

Christopher Dell Isola 

Mr. & Mrs. Albert K. Der 


Peggy & Michael Diab 

Dick’s Sporting Goods 

Cheryl Downing 

Charlie & Gaynell Downs 

Walter & Kathleen Eason 

Charles Eil, M.D. 

Howard J. Eisen, M.D. & Judith E. Wolf, M.D. 

James Epping 

in Honor of Paige, Mimi, Gerald, & Ethan 

Irl L. Extein, M.D. 

Laura C. Ferraina in Honor of Kerry Rugens 

Dr. Mary E. Wilson & Dr. Harvey V. Fineberg 

Mitchell S. Finkel 

in Memory of Dorothy Warbritton 

Seth P. Forster 

Rudolph M. Franklin, M.D. 

Albert M. Friedman 

in Memory of Albert Cohen 

Jason Garver 

Marie C. Gelato 

Katherine Gerhardt 

Glyde Clothing 

Martin I. Goldenberg, Ph.D. 

George Green 

Sarah Gregg 


Kenneth D. Guidry 

Calvin Hackeman & Eric Hunsley 

Taira A. Hall 

Dr. John T. Hammack 

Corwin & Gloria Hansch 

Mary Harris 

Jeanette Haskell 

in Honor of Coyley Haskell 

& Michael Sheehan 

Lavonne C. Howard 


Mark J. Huebsch 

Steve Jacobs, O.D., M.A. 

Stephanie L. James, M.D. 

Pamela Jeffcoat 

Eric Johnson 

Thomas & Carolyn Johnson 


Wolfgang K. Joklik, D.Phil. 

David Kahrnoff 

Dr. Stuart Kassan 

Jeffrey Kelly 

Dr. Thomas J. Kennedy, Jr., Trust 

Alexander Klayman 

Gary & Margot Knight 

Richard M. Krause, M.D. 

Ted & Wendy Lawrence 

Gottfried F. H. Lehmann, M.D. 

Michael Lentini 

Gail Levine, MA, CCRC 

Paula Levine in Honor of Saul & Phyllis Oresky 

Carol S. Lidz, Psy.D. 

Paul S. Lietman 

Gerald Lippert in Memory of David Johnson 

William D. Lippman 

Dr. Joseph & Mrs. Anita Loscalzo 

Esther Lumsdon 

Manassas Gap Woman’s Club 

Bruce Marine 


Anne Alexander Marshall, Ph.D. & 

Mr. Davis Marshall 

David & Sandra Martin 

G. Richard Marzolf 


Charles A. McCallum, D.M.D., M.D. 

Brenden Mecleary 

Meredith, Bair, Peacock, McDonald & 

McMullan, P.C. in Memory of Harold Fullmer 

Capt. W.A. Millar II, D.Ph. 

Miltenyi Biotec, Incorporated 

Kathy Moran 

Barbara M. Morgan, Ph.D. 

in Memory of John “Eddie” Pead 

Morton L. Moss, M.D. 

David Myers in Memory of Dov Kadmon 

Paul Neiman, M.D. 

Donna Nichols 

Judith Nienberg 

Arthur W. Nienhuis, M.D. 

David & Johanna Noble 

Robert & Nancy Nuttelman 

Cecilia Y. Oh 

Peter & Gertraut PaleseSandhya Patel 

in Memory of Maryanne McCauley 

Fred J. Payne, M.D., M.P.H. 

Clarence & Sue Petty 

in Memory of Harold Fullmer 

Judy Popiel 

Paul G. Poulin 

Premier Institute 


Susan Press in Honor of Florence & Jo Crozier 

John & Janet Przygoda 

in Memory of Alvan Fisher 

Mr. & Mrs. Arnold C. Rausch 

in Memory of Nancy Lezon 

James & Lisa Reinish 

Gordon & Charlene Robertson 


Mark & Pam Roden 

Dr. Jonathan Rothblatt 

Carolena Saccone & Matt Grimaldi 

Joyce & Jerry Sachs 

Jane Saffell in Memory of Alvan Fisher 

Mrs. Lili-Charlotte J. Sarnoff 

Benjamin Sherman 

Amy J. Siller 

Robert W. & Glenna R. Simpson 

Charles R. Simrell, M.D. & Deborah L. Giles 

Gail Skowron, M.D. in Memory of Alvan Fisher 

Dr. Alexander Small 

in Memory of Catherine Small 

Smithgroup in Memory of Khiem Duy Nguyen 

Maria Patrizia Somavilla 

Victor Sparaccio 

Moncrieff & Lois Spear 

James & Brenda Speller 


Juli Staiano & Marc Washington 


Donors 

Matthew & Elizabeth Steger 

Dr. Joan A. Steitz 

Barbara G. Sterm 

Robert & Emily Stevens 

Alice Tabor 

The Boston Consulting Group 


Samuel & Paula Thier 

Marcelo Todd 

Danh & Dao Tran 


Dr. & Mrs. Roy S. Weiner 

I. Bernard Weinstein 

David Wholley & Mary M. O’Crowley 

Rosie Williams in Memory of Kenneth Adams 

Julia & Howard Wolf-Rodda 

Stuart H. Yuspa, M.D. 

Wilma Zimmerman 

in Honor of Charles Zimmerman 

Gifts of less than $100 

Anonymous (9) 

A. Alan & Suzanne Adler 

Constance D. Andrews 


Dr. Philip W. Askenase 

William Barina 

Mike & Darlene Barnes 


Joseph R. Barrie 

Maria & Daniel Barry 

Mona Baumgarten 

in Honor of Saul & Phyllis Oresky 

Vivian D. Beckenbaugh 

Stuart Berger & Timothy J. Leary 

in Memory of Adam J. Berry 

Stephen N. Berk 

in Memory of Angela Denise Winfrey 

Lee Bird 

Margo Bradford 

Robert L. & Patty M. Browne 

Scott W. Browning & Joanne T. Ahearn 


Elise Bruml 

Bertha E. Bryant 

Sandra Calderon in Honor of Dorothy Vining 

Kendall & Jacqueline Capecci 


V. R. Carlson 

Raymond Carlson 

Ana M. Caro & Mr. Nobuaki Nakashima 


Janis Carter in Memory of Alvan Fisher 

Jill Castleman in Honor of Lawrence Center 

M. Claudia Cauterucci 

Raymond & Gloria Cekalla 

Stephen M. Chaplin 

Charles Schwab Foundation 

Matthew & Melissa Charles 

Linda Christiansen 


Leah M. Cochol in Memory of Barry Moore 

Nancy & Michael Cohen 


Susan M. Cole 

Jean C. Conran 

Richard Conway 

Donna Conwell 


Lois B. Cook in Memory of Stephen Liptak 

Paul Coppola 

Eva & Joe Coyne 

Richard & Arlene Crowell 

A. Blair Crownover 


Mrs. Mary Curnen 

Dr. Marion Danis 

Kiron Das 

Maritza Gil De Lamadrid 

The Degoff Family in Memory of Alvan Fisher 

Delhi Dhaba Restaurant 

Wanda Billingsley DeLorge 


Christina & Matt Devine 

Christine M. Devries 


Leanne Dolin 

James Douglas 

Mark S. Drapkin, M.D. 

James S. Dye 

Easton Lodge in Memory of Dr. Robert Childs 

Alta Eisenpress 

Richard W. Erbe, M.D. 

in Memory of Herbert Sober 

Pamela Erskine in Memory of Alvan Fisher 

Herbert & Seralyn Faber 


Richard & Sheila Farmer 

Carol Feichter in Honor of Dorcas Harris 

Karen & Paul Feldman 


Barbara Fender 


Joanne & Howard Fisher 


Ford Agency, Inc. 


Charles & Myrna Ford 

in Memory of Harold Fullmer 

Henry W. Foster, M.D. 

Mr. & Mrs. Terry R. Frechem 


Richard & Fay Froh 


Hellen P. Galvin 

Ciro A. Gamboni 

in Memory of Margaret Phillips 

F. Harold Giedt 

Edgar & Carol Gilbert 

Dr. Eli Glatstein 

Irving D. Goldberg 

Neil & Ann Gordon 

in Honor of Cliff & Sandy Northup 

Holly Gorse & Family 


Arlene Gottlieb 


Dr. & Mrs. Michael Gottlieb 

Thomas H. Gouard 

Elaine Gray in Memory of Khiem Duy Nguyen 

Allison Greenstein 

in Memory of Jesse & Lucy Greenstein 

The Grigg Family 


Kathy Guire 

Richard & Mary Haden 


Mark, Claire, Lauren & Patrick Haley 


S. Sean Hamashige 

Jeff Hargett 

Mary E. Hart 

Jack Hawkins 

Ann Heiney 

John Hermes Family 


Blanche H. Heston 

Kimberly F. Hockaday 


Nancy Hoffman in Memory of Alvan Fisher 

Todd & Carolyn Hollis 

Julie Holm 

Wendy Jacobs in Memory of Dr. Robert Childs 

Michelle Jezycki 

Elizabeth S. Johns 

JustGive.org 

Allen P. Kaplan, M.D. 

Carol Anne Kelly 


Dr. Anthony Kirincich 

Kelly Knapp 

Wilda & Thomas Knox 


Melinda & Thomas Knuppel 

Deloris E. Koziol, Ph.D. 

Thomas Kramer 

Donna Krasnewich & Jaro Vostal 

Herman F. Kraybill, Ph.D. 

Jo Anne D. Kysar Bickham 

Mr. & Mrs. Steven Labbe 

in Memory of Helen Badalucca 

Daniel & Kristin Labezius 

in Memory of Barry Moore 


Donors 

Monika Last 

Carl Julian Lauter 

Jeffrey Layn 

Mr. & Mrs. Harry E. Ledbetter 

in Memory of Homer Baughman 

David & Debbie Lee 

Elaine Lee 

Tatyana Leifman in Memory of Alvan Fisher 

Dr. David L. Levin 

Dr. Douglas M. & Susan S. Levin 

Drs. Judith & Jonathan Levin 

Robert J. Levine, M.D. 

Mrs. Frances Lezon in Memory of Nancy Lezon 

Thomas Locastro 

Gwilym S. Lodwick, M.D. 

Sandra & Charles Longer 

in Memory of Jerry Jennings 

Roye L. Lowry 

M&R First Shift-Nabisco 


Judy & Jerry Macks 

John S. Maher 

Philip C. Mahoney 

John Makulowich 

Robert & Dolores Markley 

in Memory of David McGrath 

Stan Mason in Memory of Barry Moore 

Edward & Janice Maxwell 


Andrew K. McAllister 

Mr. & Mrs. Andrew McAllister 

Mrs. J. Kris McClain 

Norma McCowin 

Sarajane McInnes 

Gary & Patricia McLane 


Matthew McLaughlin 

F.H. McPeak in Memory of Kenneth Adams 

Medical Research Consulting Services 

Cheryl & Reynario Melencio 

Dr. & Mrs. Henry Metzger 

Joseph A. Micucci 

Anton & Alice Mika 

Jimmy & Karen Miller 


Bert & Lyne Molow 

in Memory of Charles Appel 

Douglas & Angelika 


Fairy S. Moore in Memory of Kenneth Adams 

Takisha Morgan in Honor of Barbara Tucker 

Dr. Tom M. Morse 

John MulhernNicklas Musgrave 

in Memory of Dr. Robert Childs 

Ronald & Mary Frances Myers 

David Neuman 

Colleen & Robert Newman 

Eva Newman & Family 

in Memory of Gloria Price 

Jeffrey & Ellen Nissen 

Zipporah Nyaga 

Rick & Nancy O’Brien 

Dr. Robert K. Ockner 

Mary Michelle O’Hara-Levin 

Diana Oresky 

Owen N. Owunwanne 

Suzanne & Bernard Paley 

in Memory of Beatrice Siegel 

Debra L. Parrish 

Michael Ian Paul, M.D. 

Jorge Perez-Cruet 

Marlene M.P. Peterson 


Lacy Pezold 

Alan & Chang Philippi 

Suwat Phruksawan 

Todd & Parker Poling 

Judy Potts 

Celestine & Willie Price 


Mr. & Mrs. Robert Price 


Thomas J. Purtell in Memory of Alvan Fisher 

Alfred Quirouet, Jr. & Ellen Thomason 


Dr. Sidney Raffel 

Gay & Scott Ramsey 

in Memory of Steve McKinley 

Michael & Stephanie Reed 


Richard & Terry Roach 

in Honor of Kristen R. Thompson 

Richard & Renata Robertson 


Noemi B. & Roberto A. Rodriguez 

Sara Rosen in Honor of Saul & Phyllis Oresky 

Esther Rosenstock 

Douglas & Barbara Rosing 


Cheryll Rothery-Jackson, Psy.D. 


Robert Ruijssenaars 

Ellen Saideman & Peter Margulies 


Mrs. Annette Sallet in Memory of Alvan Fisher 

Chad Sanford 

James Scarborough 

Rosemary H.S. Scarborough 


Alan & Geraldine Schechter 

Roslyne Schulman 


Chianti Cohen Seitz 

Shanna Shadoan in Honor of Paul Sica 

Catherine P. Sheehy 

Ashley Shelton 

Wayne Shewmaker 

Linda G. Silversmith 

in Honor of Janice Weymouth 

Andrea Simmons in Memory of Nancy Lezon 

Dr. Douglas L. Smith, Ph.D. 

Joseph W. Smith & Peggy Jo Rutherford 

Harlan & Bethany Sonderling 


Pamela & John Spears 

Earl & Gisela Sprouse 

Richard Stevens in Memory of Alvan Fisher 

Alison H. Stigers 

Lorre Stottlemyer 

Susan K. Sullivan 

Jeanine Superata 


The Swanson Family 


Donald C. Syracuse, M.D. 

Samuel & Lily Takahashi 

Yasuko & Kosuke Tanaka 

in Memory of Jerry Jennings 

The University of Alabama Educational 

Foundation in Memory of Harold Fullmer 

Carrie Thomas in Memory of John “Eddie” Pead 

Dr. John R. Ticehurst 

in Honor of Robert Chanock 

Barbara Tomar 


Connie Trantow & Jay Mitchell 

Keturah A. Underdue 

Dr. Boris Vaisman 

Marjorie W. Vanderbilt 


Alice W. & George A. Vdovin 

Linda Wegweiser in Honor of Michael Lazzara 

Anne & Duncan Wells 

in Memory of Barry Moore 

Michael & Nancy Wherry 


Glenn G. & Monica A. Whiteside 

Susan Wiener 

Rachel Witsaman 

Bruce McLaren Wolfe 

Dr. Yining Xie 

Gifts In Kind 

Affymetrix Inc 

Mark & Dora Bell 

Broad Institute 

Erika Ginsburg 

Perlegen Sciences, Inc 

Pfizer Inc 

Kermit Richard 

Dave & Julie Shoemaker 


Board of Directors 

Executive committee 

Charles A. Sanders, M.D. 

Chairman 

Retired Chairman & CEO 

Glaxo, Inc. 

The Honorable John Edward Porter 

Vice Chairman 

Hogan & Hartson LLP 

Paul M. Montrone, Ph.D. 

Treasurer 

Chairman 

Perspecta Trust 


Secretary 

Director Emeritus 

Albert & Mary Lasker Foundation 

Board of directors 

Kathy Bloomgarden, Ph.D. 

Chief Executive Officer 

Ruder Finn Inc. 

Mrs. William N. Cafritz 

Trustee 

The John F. Kennedy Center for the 

Performing Arts 

Mr. Mark D. Ein 


Venturehouse Group LLC 

Mr. Miles Gilburne 

Managing Member 

ZG Ventures, LLC 


Managing Director 

Burrill & Company 

Ms. Sherry Lansing 


The Sherry Lansing Foundation 


Chairman and Chief Executive Officer 

AlphaMed Consulting, Inc. 

Steven M. Paul, M.D. 

Executive Vice President, Science and Technology 

President, Lilly Research Laboratories 



Dean 

Stanford University School of Medicine 

Mrs. Jillian Sackler, D.B.E. 

President and CEO 

AMS Foundation for the Arts, Sciences 

& Humanities 


Chairman 

The Edmond J. Safra Philanthropic Foundation 

Ellen V. Sigal, Ph.D. 

Chairperson 

Friends of Cancer Research 

Solomon H. Snyder, M.D. 

Distinguished Service Professor of Neuroscience, 

Pharmacology, and Psychiatry 

Solomon H. Snyder Department of Neuroscience 

Johns Hopkins University School of Medicine 

Stephen P. Spielberg, M.D., Ph.D. 

Professor of Pediatrics and of Pharmacology 

and Toxicology 

Dartmouth Medical School 

Patrick C. Walsh, M.D. 

University Distinguished Service Professor 

James Buchanan Brady Urological Institute 

Johns Hopkins Medical Institutions 

Ex Officio Non-Voting 

Elias A. Zerhouni, M.D. 

Director 


Andrew C. von Eschenbach, M.D. 

Commissioner 

Food and Drug Administration 

Emeritus 

Paul Berg, Ph.D. 

Cahill Professor in Biochemistry (Emeritus) 

Stanford University School of Medicine 

Honorary 


Distinguished University Professor 

Hylda Cohn/American Cancer Society 

Professor of Clinical Oncology and 

Professor, Department of Radiation Oncology 

Drexel University College of Medicine 


Advisory Boards 

Grand Challenges in Global Health 

Scientific Board 

Harold Varmus, M.D. 

Chair of Board and Executive Committee 

President and Chief Executive Officer 

Memorial Sloan-Kettering Cancer Center 

United States 

Tadataka (Tachi) Yamada, M.D. 

Member, Executive Committee 

President 

Global Health Program 


United States 

Elias A. Zerhouni, M.D. 

Member, Executive Committee 

Director 


United States 

Sir Roy Anderson, Ph.D., F.R.S. 

Head, Department of Infectious Disease Epidemiology 

Imperial College of the University of London 

United Kingdom 

Alan Bernstein, O.C., Ph.D., F.S.R.C. 

Executive Director 

Global HIV Vaccine Enterprise 

United States 

Mary Jane Cardosa, D.Phil. 

Professor of Virology 

Institute of Health and Community Medicine 

Universiti Malaysia Sarawak 

Malaysia 

Pierre Chartrand, Ph.D. 

Acting President 

Canadian Institutes of Health Research 

Canada 

Christine M. Debouck, Ph.D. 

Pharmaceutical & Biotechnology Consultant 

United States 


Director 

National Institute of Allergy and Infectious Diseases 


United States 

William H. Foege, M.D., M.P.H. 

Senior Fellow 

Global Health Program 


United States 

Nirmal Kumar Ganguly, M.D. 

Former Director General 

Indian Council for Medical Research 

Julie Louise Gerberding, M.D., M.P.H. 

Director 

Centers for Disease Control and Prevention 

United States 

Fotis C. Kafatos, Ph.D. 

Chair in Insect Immunogenetics 

Department of Biological Sciences 

Faculty of Life Sciences 

Imperial College London 


Gerald Keusch, M.D. 

Assistant Provost for Global Health, Medical Campus 

and Associate Dean for Global Health 

Boston University School of Public Health 

United States 

Francis Kwesi Nkrumah, M.D., Ph.D 

Former Director 

Noguchi Memorial Institute for Medical Research 

University of Ghana, ACCRA 

Ghana 

Sir Gustav Nossal, Ph.D., F.R.S. 

Department of Pathology 

University of Melbourne 

Australia 

Odile Puijalon, Ph.D. 

Unite d’Immunologie Moleculaire des Parasites 

Institut Pasteur 

France 

Yiming Shao, M.D., Ph.D. 

Chief Expert on AIDS 

Chinese Center for Disease Control and Prevention 

(China CDC) 

Director, Division of Research on Virology and 

Immunology 

National Center for AIDS/STD Control and 

Prevention (NCAIDS), China CDC 

China 



Peter A. Singer, M.D., M.P.H., F.R.C.P.C, F.R.S.C. 

Senior Scientist, McLaughlin-Rotman Centre, 

University Health Network 

Senior Scientist, McLaughlin Centre for Molecular 

Medicine 

Professor of Medicine, University of Toronto 

Distinguished Investigator, Canadian Institutes of 

Health Research 

Canada 

Mark J. Walport, Ph.D., MB. BChir. 

Director 

The Wellcome Trust 


Florence Wambugu, Ph.D. 

President 

A Harvest Biotech Foundation International (AHBFI) 

Kenya 

Yongyuth Yuthavong, Ph.D. 

Senior Scientist 

National Science and Technology 

Development Agency 

Thailand 

Genetic Association information 

Network (GAIN) Steering Committee 

James F. Battey, Jr., M.D., Ph.D. 

Director 

National Institute on Deafness and other 

Communication Disorders (NIDCD) 

and Chair, NIH Stem Cell Task Force 

Michael Brown, M.D. 

Regental Professor 

Director, Jonsson Center for Molecular Genetics 

The University of Texas Southwestern Medical Center 

at Dallas 

Gregory L. Burke, M.D., M.S. 

Professor and Chair 

Department of Public Health Sciences 

Wake Forest University School of Medicine 

*Francis S. Collins, M.D., Ph.D. 

Director 

National Human Genome Research 

Institute (NHGRI) 

Peter J. Donnelly, Ph.D. 

University of Oxford 

Department of Statistics 

Gary H. Gibbons, M.D. 

Director, Cardiovascular Research Institute 

Professor of Medicine 

Morehouse School of Medicine 

Jack M. Guralnik, M.D., Ph.D. 

Senior Investigator and Chief, Laboratory of 

Epidemiology, Demography, and Biometry 

National Institute of Aging (NIA) 

Katrina Gwinn-Hardy, M.D. 

Program Director, Extramural Research Program 

National Institute of Neurological Disorders 

and Stroke (NINDS) 

Robert Hoover, M.D., Sc.D. 

Director, Epidemiology and Biostatistics Program 

National Cancer Institute (NCI) 

*Thomas R. Insel, M.D. 

Director 

National Institute of Mental Health (NIMH) 

Bartha M. Knoppers, L.L.B., Ph.D. 

Canada Research Chair in Law and Medicine 

Université de Montréal 

*Eric S. Lander, Ph.D. 

Director, Broad Institute of MIT and Harvard 

Professor of Biology, MIT 

Professor of Systems Biology, Harvard Medical School 

Member, Whitehead Institute for Biomedical Research 

Richard P. Lifton, M.D., Ph.D. 

Chairman, Department of Genetics, 

Professor of Medicine (Nephrology), Genetics & 

Molecular Biophysics & Biochemistry 

Associate Investigator, Howard Hughes 

Medical Institute 

Yale University School of Medicine 

Yvonne Maddox, Ph.D. 

Deputy Director 

National Institute of Child Health and Human 

Development (NICHD) 

*Elizabeth G. Nabel, M.D. 

Director 

National Heart, Lung, and Blood Institute (NHLBI) 

*Member, GAIN Executive Committee 



Ross Prentice, Ph.D. 

Professor, Biostatistics 

Fred Hutchinson Cancer Research Center 

Griffin Rodgers, M.D. 

Deputy Director 

National Institute of Diabetes and Digestive and 

Kidney Diseases (NIDDK) 

*Albert Seymour, Ph.D. 

Director and Head of Biological Profiling 

Pfizer Pharmacogenomics 

Ralph Snyderman, M.D. 

Former Chancellor for Health Affairs and President 

and CEO 

Duke University Health System 

Sharon F. Terry, M.A. 

President and CEO 

Genetic Alliance, Inc. 

Vacant 

Affymetrix Inc 

The Biomarkers Consortium 

Executive Committee 

Charles Sanders, M.D. 

Chairman 


Stephen Eck, M.D., Ph.D. 

Vice President, Translational Medicine & 

Pharmacogenomics 


Thomas Insel, M.D. 

Director 

National Institute of Mental Health 

ShaAvhrée Yvette Buckman, M.D., Ph.D., F.A.A.P. 

Acting Director, Office of Translational Sciences 


John Niederhuber, M.D. 

Director 

National Cancer Institute 

Perry Nisen, M.D., Ph.D. 

Senior Vice President, Clinical Pharmacology and 

Discovery Medicine 


Steven Paul, M.D. 

Board Member, Foundation for NIH 

Executive Vice President, Science and Technology 

President, Lilly Research Laboratories 


Sara Radcliffe, M.P.H. 

Vice President, Scientific and Regulatory Affairs 

Biotechnology Industry Organization 

Daniel Schultz, M.D. 

Director, Center for Devices and Radiological Health 


Ellen Sigal, Ph.D. 

Board Member, Foundation for NIH 

Chairperson, Friends of Cancer Research 

Barry M. Straube, M.D. 

Chief Medical Officer and Director, Office of Clinical 

Standards and Quality 

Centers for Medicare and Medicaid Services 

Lawrence Tabak, D.D.S., Ph.D. 

Director, National Institute of Dental and 

Craniofacial Research 

Janet Woodcock, M.D. 

Director, Center for Drug Evaluation and Research 


Mary Woolley, M.A. 

President and Chief Executive Officer 

Research!America 

Garry Neil, M.D. 

Corporate Vice President, Corporate Office of Science 

and Technology 

Johnson & Johnson Pharmaceutical Research & 

Development 

*Member, GAIN Executive Committee 


Foundation for NIH Staff 

office of the executive director 

Amy McGuire Porter 

Executive Director 

Ann Ashby 

Deputy Executive Director 

Gary R. Barbarash, M.B.P.A. 

Senior Advisor, Operations and Management 

Kathy Guire 

Operations Administrative Officer 

Keturah Underdue 

Executive Assistant, Office of the Executive Director 

Elizabeth Johns 

Executive Correspondence Assistant 

FINANCE 

Julie Tune, C.P.A., C.F.E. 

Chief Financial Officer 

Eva Coyne 

Accounting Manager 

Noemi B. Rodriguez 

Staff Accountant 

Peggy J. Gerlacher 

Operations Associate 

EVENTS AND MARKETING 

Richard M. Scarfo 

Director, Events and Marketing 

& Assistant to the Executive Director for Board Relations 

Peggy M. Diab 

Manager, Events and Marketing 

Chianti Cohen Seitz 

Events Coordinator 

Jlynn J. Frazier, M.A. 

Coordinator, Events and Marketing 

Kristen H. Weymouth 

Assistant, Events and Marketing 

PUBLIC AFFAIRS & COMMUNICATIONS 

Charles R. Pucie, Jr. 

Director, Public Affairs and Communications 

New headquarters 

The Foundation for NIH moved into its new headquarters 

in November. The new offices are just a mile from the NIH 

campus. The foundation’s main telephone number and staff 

e-mail addresses have not changed. 

PARTNERSHIP DEVELOPMENT 

Julie Wolf-Rodda 

Director, Partnership Development 

Shawn Neil 

Manager, Development Systems 

Alison Drone 

Partnership Development Officer 

Zipporah Nyaga, M.B.A. 

Executive Assistant, Partnership Development 

GRAND CHALLENGES IN GLOBAL HEALTH 

Daniel J. Carucci, M.D., Ph.D. 

Director of Science 

& Director, Grand Challenges in Global Health 

Stephanie James, Ph.D. 

Deputy Director, Grand Challenges in Global Health 

& Associate Director of Science 

Michael Gottlieb, Ph.D. 

Associate Director of Science 

Susan Wiener, M.A. 

Project Manager, Grand Challenges in Global Health 

Heather Weingardt 

Executive Assistant 

Jan Fowler 

Executive Assistant 

The BIOMARKERS CONSORTIUM 

David Wholley 

Director, The Biomarkers Consortium 

David Lee, M.P.A. 

Deputy Director, The Biomarkers Consortium 

Maria Vassileva, Ph.D. 

Program Manager, The Biomarkers Consortium 

Chris Boshoff, Ph.D. 

Program Manager, The Biomarkers Consortium 

Shawnmarie Mayrand-Chung 

Senior Advisor, The Biomarkers Consortium 

NIH Detailee–Part-time 

Antonio Madrid 

Executive Assistant, The Biomarkers Consortium 

Cheryl Melencio 

Executive Assistant, The Biomarkers Consortium 

COMREHENSIVE T CELL VACCINE 

IMMUNE MONITORING CONSORTIUM 

Gail Levine, M.A., C.C.R.C. 

Project Manager 

Lindsey Caldwell 

Research Assistant 


Realizing the aims of foundation 

initiatives is often beyond the 

capacity of any single sector of 

America’s health-research enterprise. 

Often they are large-scale and 

complex. They must leverage the resources and insights 

special to all stakeholders—government, industry, patient 

groups, academia, and other private groups. Foundation publicprivate 

partnerships epitomize the aim Congress had in mind 

when it established the Foundation for NIH to support the 

mission of the National Institutes of Health. 

—The Honorable John Edward Porter 

Vice Chairman, Foundation for NIH

9650 Rockville Pike 

Bethesda, MD 20814-3999 USA 

301-402-5311 

www.fnih.org 

2

2007 Annual Report - Foundation for the National Institutes of Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?